The New England Journal of Medicine
e-mail icon  FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |    Advanced Search
Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe
 
Original Article
PreviousPrevious
Volume 338:153-160 January 15, 1998 Number 3
NextNext

SYT–SSX Gene Fusion as a Determinant of Morphology and Prognosis in Synovial Sarcoma
Akira Kawai, M.D., Ph.D., James Woodruff, M.D., John H. Healey, M.D., Murray F. Brennan, M.D., Cristina R. Antonescu, M.D., and Marc Ladanyi, M.D.

 Sign up for free e-toc
 

This Article
-Full Text
- PDF

Commentary
-Editorial
 by Rabbitts, T.H.
-Letters

Tools and Services
-Add to Personal Archive
-Add to Citation Manager
-Notify a Friend
-E-mail When Cited

More Information
-PubMed Citation
ABSTRACT

Background Synovial sarcomas account for up to 10 percent of soft-tissue sarcomas and include two major histologic subtypes, biphasic and monophasic, defined respectively by the presence and absence of glandular epithelial differentiation in a background of spindle tumor cells. A characteristic SYT–SSX fusion gene resulting from the chromosomal translocation t(X;18)(p11;q11) is detectable in almost all synovial sarcomas. The translocation fuses the SYT gene from chromosome 18 to either of two highly homologous genes at Xp11, SSX1 or SSX2. SYT–SSX1 and SYT–SSX2 are thought to function as aberrant transcriptional regulators. We attempted to determine the influence of the two alternative forms of the SYT–SSX fusion gene on tumor morphology and clinical outcome in patients with this sarcoma.

Methods We analyzed SYT–SSX fusion transcripts in 45 synovial sarcomas (33 monophasic and 12 biphasic) by the reverse-transcriptase polymerase chain reaction and compared the results with relevant clinical and pathological data.

Results The SYT–SSX1 and SYT–SSX2 fusion transcripts were detected in 29 (64 percent) and 16 (36 percent) of the tumors, respectively. There was a significant relation (P = 0.003) between histologic subtype (monophasic vs. biphasic) and SSX1 or SSX2 involvement in the fusion transcript: all 12 biphasic synovial sarcomas had an SYT–SSX1 fusion transcript, and all 16 tumors that were positive for SYT–SSX2 were monophasic. Kaplan–Meier analysis of 39 patients with localized tumors showed that the 15 patients with SYT–SSX2 had significantly better metastasis-free survival than the 24 patients with SYT–SSX1 (P = 0.03 by multivariate analysis; relative risk, 3.0). There were no significant correlations between the type of SYT–SSX transcript and age, sex, tumor location and size, whether there were metastases at diagnosis, or whether patients underwent chemotherapy. Histologic subtype alone was not prognostically important.

Conclusions The type of SYT–SSX fusion transcript correlates with both the histologic subtype and the clinical behavior of synovial sarcoma. SYT–SSX fusion transcripts are a defining diagnostic marker of synovial sarcomas and may also yield important independent prognostic information.


Source Information

From the Departments of Surgery (A.K., J.H.H., M.F.B.), Pathology (J.W., C.R.A., M.L.), and Human Genetics (M.L.), Memorial Sloan-Kettering Cancer Center, New York.

Address reprint requests to Dr. Ladanyi at the Department of Pathology, Memorial Sloan-Kettering Cancer Center, 1275 York Ave., New York, NY 10021.

Full Text of this Article


Related Letters:

Fetal Sex and Hemolytic Disease from Maternal Red-Cell Alloimmunization
Ulm B., Ulm M. R., Panzer S.
Extract | Full Text  
N Engl J Med 1998; 338:1699-1700, Jun 4, 1998. Correspondence

This article has been cited by other articles:



HOME  |  SUBSCRIBE  |  SEARCH  |  CURRENT ISSUE  |  PAST ISSUES  |  COLLECTIONS  |  PRIVACY  |  TERMS OF USE  |  HELP  |  beta.nejm.org

Comments and questions? Please contact us.

The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved.